The company has opened up a new office in Andover, Massachusetts, which features a showroom with Ntensify mRNA production technologies
Belgian biotechnology company Univercells has announces the opening of the first United States offices for the group.
Located in Andover, Massachusetts, the office is already up and running, and features a showroom with Ntensify mRNA production technologies from portfolio company, Quantoom Biosciences.
A launch event is being held on the day of release, September 26, 2023, and the location will then be accessible to customers and prospects as of October 2023.
So far, we have received tremendous support and excitement from existing shareholders, academia, and customers
- Hugues Bultot, CEO of Univercells
“Since the inception of Univercells in Brussels, Belgium in 2013, we have been vocal about wanting to expand into the United States. With customers, shareholders and investors already based in the US, this expansion allows our group to leverage our strong proprietary infrastructure via the Belgium sites here in Andover to deepen those relationships,” said Hugues Bultot, CEO of Univercells.
“We are thrilled to see these plans come to fruition and to bring our technologies, CDMO and advisory services across the border with an office and labs that allow us to highlight the different affiliates within the group. So far, we have received tremendous support and excitement from existing shareholders, academia, and customers, which makes us confident and enthusiastic for the future,” Bultot continued.
The new office and lab space is located at Andover Park. The site was recently redeveloped by Celera Properties and True North Management Group into a cutting-edge hub for life-science innovation.
Univercells Group has a total of 800 sqm of offices and labs, ready to welcome new colleagues. The US branch is growing rapidly and is actively recruiting scientific and commercial profiles to expand its headcount.
“Our goal is to be a critical partner to customers that need high quality and reliable support for complex viral vector and nucleic acid projects quickly and cost-efficiently. But understandably, prospects and investors can see challenges with doing business across a global border,” said José Castillo, Co-Founder and CEO of Quantoom Biosciences continued.